Literature DB >> 19401628

Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection.

A Danielle Iuliano1, Eleanor Feingold, Abdus S Wahed, David E Kleiner, Steven H Belle, Hari S Conjeevaram, Joseph Zmuda, T Jake Liang, Leland J Yee.   

Abstract

Hepatic steatosis is the accumulation of fat in liver cells. Insulin resistance (IR) occurs when normal amounts of insulin do not stimulate insulin activity in cells. Both conditions have been described in hepatitis C virus (HCV) infection and are thought to be biologically related. This study examined the association of genetic variants with steatosis and IR among 167 African Americans and 184 Caucasian Americans with HCV genotype-1. Steatosis was defined as at least 5% of fat in cells on liver biopsy. IR was quantified as a score greater than 2 from the Homeostasis Model Assessment, version 2.2 (HOMA2-IR). Associations were investigated by estimating odds ratios separately by race. Statistically significant associations (p < 0.05) were observed for variants in interleukin-10 (IL10), leptin receptor (LEPR), interleukin-6 (IL6) and transforming growth factor beta-1 (TGF-beta1) for both outcomes. Some significant interactions were observed between IL10,LEPR and TGF-beta1 polymorphisms and HOMA2-IR scores when examining steatosis. The interaction of HOMA2-IR and IL10 was consistent in both races whereas for LEPR and TGF-beta1 the interactions were statistically significant in only one of the racial groups.These results could imply that some IL10,LEPR and TGF-beta1 polymorphisms may modify an association between steatosis and IR. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401628      PMCID: PMC2803674          DOI: 10.1159/000214380

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  28 in total

Review 1.  Insulin resistance syndrome.

Authors:  G Rao
Journal:  Am Fam Physician       Date:  2001-03-15       Impact factor: 3.292

Review 2.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

Review 3.  Epidemiology of nonalcoholic fatty liver.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Clin Liver Dis       Date:  2004-08       Impact factor: 6.126

4.  Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.

Authors:  Xiaowen Su; Leland J Yee; KyungAh Im; Shannon L Rhodes; YongMing Tang; Xiaomei Tong; Charles Howell; Darmendra Ramcharran; Hugo R Rosen; Milton W Taylor; T Jake Liang; Huiying Yang
Journal:  J Hepatol       Date:  2008-05-20       Impact factor: 25.083

Review 5.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

6.  Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.

Authors:  J M Petit; J B Bour; C Galland-Jos; A Minello; B Verges; M Guiguet; J M Brun; P Hillon
Journal:  J Hepatol       Date:  2001-08       Impact factor: 25.083

7.  Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection.

Authors:  Jason M Hui; James Kench; Geoffrey C Farrell; Rita Lin; Dev Samarasinghe; Christopher Liddle; Karen Byth; Jacob George
Journal:  J Gastroenterol Hepatol       Date:  2002-08       Impact factor: 4.029

8.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

9.  Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

Authors:  Jason M Hui; Archana Sud; Geoffrey C Farrell; Priyanka Bandara; Karen Byth; James G Kench; Geoffrey W McCaughan; Jacob George
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

10.  The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.

Authors:  Heather M Patton; Keyur Patel; Cynthia Behling; David Bylund; Lawrence M Blatt; Marc Vallée; Shanon Heaton; Andrew Conrad; Paul J Pockros; John G McHutchison
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

View more
  3 in total

1.  Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.

Authors:  Ali Afsari; Edward Lee; Babak Shokrani; Tina Boortalary; Zaki A Sherif; Mehdi Nouraie; Adeyinka O Laiyemo; Kawtar Alkhalloufi; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2017-06-13       Impact factor: 3.199

2.  Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic Hepatitis C virus infection.

Authors:  Ahlam M Ahmed; Magda S Hassan; Alaa Abd-Elsayed; Huwayda Hassan; Ahmad F Hasanain; Ahmed Helmy
Journal:  Saudi J Gastroenterol       Date:  2011 Jul-Aug       Impact factor: 2.485

3.  Lack of association between interleukin 28B gene polymorphisms (rs8099917G/T, rs12979860 C/T) and susceptibility to chronic hepatitis C virus infection, Tehran, Iran.

Authors:  Maryam Karkhane; Seyed Reza Mohebbi; Pedram Azimzadeh; Mahsa Saeedi Niasar; Mohamad Reza Sarbazi; Afsaneh Sharifian; Afshin Mohammad Alizadeh
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2016-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.